OTCMKTS:ARGSQ Argos Therapeutics (ARGSQ) Stock Price, News & Analysis $0.05 0.00 (0.00%) As of 10/10/2019 Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Argos Therapeutics Stock (OTCMKTS:ARGSQ) Get Argos Therapeutics alerts:Sign Up Key Stats Today's Range$0.05▼$0.0550-Day Range$0.05▼$0.0552-Week Range$0.02▼$0.25VolumeN/AAverage Volume13,394 shsMarket Capitalization$571.70 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Argos Therapeutics, Inc. is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, specializing in the development of personalized immunotherapies for oncology and infectious diseases. Founded in 2007, Argos leverages its proprietary RNA‐transfected dendritic cell platform to engineer patient‐specific vaccines designed to stimulate targeted immune responses against cancer cells or chronic viral infections. The company’s lead product candidate, AGS-003, is an autologous dendritic cell vaccine in development for advanced renal cell carcinoma. Argos has also explored therapeutic programs in chronic hepatitis B and other infectious diseases by adapting its platform to present viral antigens and boost antiviral immunity. Argos Therapeutics has conducted multiple Phase II and Phase III clinical trials in North America and Europe, collaborating with academic institutions and contract research organizations to advance its pipeline. Argos Therapeutics is led by President and Chief Executive Officer Dr. Laurence J. Reid, supported by a management team with expertise in immunology, cell therapy manufacturing and clinical development. While its primary operations are based in the United States, the company’s clinical trial activities have spanned international sites to access diverse patient populations and regulatory environments. Argos continues to focus on refining its dendritic cell technology and pursuing strategic partnerships to broaden the application of its personalized immunotherapy platform.AI Generated. May Contain Errors. Read More Receive ARGSQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Argos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ARGSQ Stock News HeadlinesArgos Therapeutics (OTCMKTS:ARGSQ) and Synaptogenix (NASDAQ:TAOX) Head-To-Head ComparisonJune 7, 2026 | americanbankingnews.comUnited Therapeutics price target raised to $400 from $360 at ArgusNovember 1, 2024 | markets.businessinsider.comTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now.June 15 at 1:00 AM | Altimetry (Ad)Best Argos sale discounts, from garden furniture sets to BBQsMay 3, 2024 | uk.style.yahoo.comARGSQ Historical DataSeptember 27, 2023 | investing.comSeven Argos stores to shut NEXT month amid plans to close 100 for good by 2024July 29, 2023 | mirror.co.ukMArgos launches massive half price garden furniture sale as the heatwave continuesJune 22, 2023 | mirror.co.ukM2023-2029 mRNA Vaccines & Therapeutics Market Opportunities and ForecastApril 9, 2023 | marketwatch.comSee More Headlines ARGSQ Stock Analysis - Frequently Asked Questions How have ARGSQ shares performed this year? Argos Therapeutics' stock was trading at $0.0540 at the beginning of the year. Since then, ARGSQ stock has increased by 0.0% and is now trading at $0.0540. How were Argos Therapeutics' earnings last quarter? Argos Therapeutics Inc (OTCMKTS:ARGSQ) posted its earnings results on Wednesday, August, 9th. The biopharmaceutical company reported ($4.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.50) by $0.30. The biopharmaceutical company had revenue of $0.07 million for the quarter, compared to analysts' expectations of $0.10 million. When did Argos Therapeutics' stock split? Argos Therapeutics's stock reverse split on Friday, January 19th 2018.The 1-20 reverse split was announced on Thursday, January 18th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 18th 2018. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Argos Therapeutics? Shares of ARGSQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/09/2017Today6/15/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical Preparations Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:ARGSQ CIK1105533 Webwww.argostherapeutics.com Phone919-287-6300FaxN/AEmployees122Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$1.90 million Price / Sales0.30 Cash FlowN/A Price / Cash FlowN/A Book Value($1.63) per share Price / Book-0.03Miscellaneous Outstanding Shares10,587,000Free FloatN/AMarket Cap$571.70 thousand OptionableNot Optionable Beta2.47 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (OTCMKTS:ARGSQ) was last updated on 6/15/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredIs SpaceX really worth 1.78 Trillion?With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...InvestPub | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredSpaceX is chump change compared to Elon’s $20T ‘iPhone’Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...StocksToTrade | SponsoredThe roadshow starts Monday. This stock isn't ready.The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...Behind the Markets | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Argos Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Argos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARGSQ Stock Alerts